{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:58:15Z","timestamp":1792173495136,"version":"4.4.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s40263-012-0010-5","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T15:40:02Z","timestamp":1355758802000},"page":"1033-1049","source":"Crossref","is-referenced-by-count":216,"title":["Rediscovering Trazodone for the Treatment of Major Depressive Disorder"],"prefix":"10.1007","volume":"26","author":[{"given":"Andrea","family":"Fagiolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Comandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Catena","family":"Dell\u2019Osso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,13]]},"reference":[{"key":"10_CR1","unstructured":"World Health Organization. Depression. http:\/\/www.who.int\/mental_health\/management\/depression\/definition\/en\/ (2012). Accessed 13 May 2012."},{"key":"10_CR2","doi-asserted-by":"crossref","unstructured":"Nutt DJ, Davidson JR, Gelenberg AJ, et al. International consensus statement on major depressive disorder. J Clin Psychiatry. 2010;71(Suppl E1):e08.","DOI":"10.4088\/JCP.9058se1c.08gry"},{"issue":"9590","key":"10_CR3","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(07)61238-0","volume":"370","author":"M Prince","year":"2007","unstructured":"Prince M, Patel V, Saxena S, et al. No health without mental health. Lancet. 2007;370(9590):859\u201377.","journal-title":"Lancet"},{"key":"10_CR4","volume-title":"Practice guideline for the treatment of patients with major depressive disorder","author":"American Psychiatric Association","year":"2010","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington: American Psychiatric Association; 2010.","edition":"3"},{"issue":"2","key":"10_CR5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/15622970701227829","volume":"8","author":"M Bauer","year":"2007","unstructured":"Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry. 2007;8(2):67\u2013104.","journal-title":"World J Biol Psychiatry"},{"key":"10_CR6","doi-asserted-by":"crossref","unstructured":"Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010;71(Suppl E1):e04.","DOI":"10.4088\/JCP.9058se1c.04gry"},{"issue":"40","key":"10_CR7","first-page":"700","volume":"107","author":"M Harter","year":"2010","unstructured":"Harter M, Klesse C, Bermejo I, et al. Unipolar depression: diagnostic and therapeutic recommendations from the current S3\/National Clinical Practice Guideline. Dtsch Arztebl Int. 2010;107(40):700\u20138.","journal-title":"Dtsch Arztebl Int"},{"key":"10_CR8","unstructured":"National Institute for Health and Clinical Excellence. Depression: the treatment and management of depression in adults. http:\/\/www.nice.org.uk\/nicemedia\/live\/12329\/45888\/45888.pdf (2009). Accessed 14 Aug 2012."},{"issue":"Suppl 13","key":"10_CR9","first-page":"18","volume":"64","author":"ME Thase","year":"2003","unstructured":"Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry. 2003;64(Suppl 13):18\u201325.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"10_CR10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4088\/JCP.10m06223blu","volume":"71","author":"T Chang","year":"2010","unstructured":"Chang T, Fava M. The future of psychopharmacology of depression. J Clin Psychiatry. 2010;71(8):971\u20135.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"10_CR11","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1185\/030079906X132415","volume":"22","author":"M Machado","year":"2006","unstructured":"Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin. 2006;22(9):1825\u201337.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10_CR12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28\u201340.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10_CR13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4088\/JCP.v60n0403","volume":"60","author":"AA Nierenberg","year":"1999","unstructured":"Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60(4):221\u20135.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10_CR14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4088\/JCP.v63n0414","volume":"63","author":"AH Clayton","year":"2002","unstructured":"Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357\u201366.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 11","key":"10_CR15","first-page":"37","volume":"61","author":"M Fava","year":"2000","unstructured":"Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(Suppl 11):37\u201341.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 16","key":"10_CR16","first-page":"27","volume":"65","author":"M Fava","year":"2004","unstructured":"Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry. 2004;65(Suppl 16):27\u201332.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10_CR17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00004714-200204000-00006","volume":"22","author":"M Fava","year":"2002","unstructured":"Fava M, Hoog SL, Judge RA, et al. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol. 2002;22(2):137\u201347.","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 11","key":"10_CR18","first-page":"46","volume":"61","author":"ME Thase","year":"2000","unstructured":"Thase ME. Treatment issues related to sleep and depression. J Clin Psychiatry. 2000;61(Suppl 11):46\u201350.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl","key":"10_CR19","first-page":"S50","volume":"95","author":"JP Feighner","year":"1988","unstructured":"Feighner JP, Boyer WF. Overview of USA controlled trials of trazodone in clinical depression. Psychopharmacology. 1988;95(Suppl):S50\u20133.","journal-title":"Psychopharmacology"},{"issue":"10","key":"10_CR20","doi-asserted-by":"crossref","first-page":"734","DOI":"10.7326\/0003-4819-149-10-200811180-00008","volume":"149","author":"G Gartlehner","year":"2008","unstructured":"Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149(10):734\u201350.","journal-title":"Ann Intern Med"},{"key":"10_CR21","unstructured":"Extended-release trazodone (Oleptro) for depression. Med Lett Drugs Ther. 2010;52(1351):91\u20132."},{"issue":"10","key":"10_CR22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1017\/S1092852900024020","volume":"14","author":"SM Stahl","year":"2009","unstructured":"Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009;14(10):536\u201346.","journal-title":"CNS Spectr"},{"issue":"6","key":"10_CR23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00003495-198121060-00001","volume":"21","author":"RN Brogden","year":"1981","unstructured":"Brogden RN, Heel RC, Speight TM, Avery GS. Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs. 1981;21(6):401\u201329.","journal-title":"Drugs"},{"issue":"3","key":"10_CR24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0269881105051526","volume":"19","author":"Y Odagaki","year":"2005","unstructured":"Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005;19(3):235\u201341.","journal-title":"J Psychopharmacol"},{"key":"10_CR25","volume-title":"Stahl\u2019s essential psychopharmacology","author":"SM Stahl","year":"2008","unstructured":"Stahl SM. Stahl\u2019s essential psychopharmacology. 3rd ed. New York (NY): Cambridge University Press; 2008.","edition":"3"},{"issue":"2","key":"10_CR26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/sj.npp.1300057","volume":"28","author":"GJ Marek","year":"2003","unstructured":"Marek GJ, Carpenter LL, McDougle CJ, Price LH. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology. 2003;28(2):402\u201312.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10_CR27","first-page":"83","volume":"53","author":"AA Nierenberg","year":"1992","unstructured":"Nierenberg AA, Cole JO, Glass L. Possible trazodone potentiation of fluoxetine: a case series. J Clin Psychiatry. 1992;53(3):83\u20135.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10_CR28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(99)00644-5","volume":"383","author":"M Pazzagli","year":"1999","unstructured":"Pazzagli M, Giovannini MG, Pepeu G. Trazodone increases extracellular serotonin levels in the frontal cortex of rats. Eur J Pharmacol. 1999;383(3):249\u201357.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10_CR29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0166-2236(00)02002-6","volume":"24","author":"CB Saper","year":"2001","unstructured":"Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 2001;24(12):726\u201331.","journal-title":"Trends Neurosci"},{"issue":"12","key":"10_CR30","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1017\/S1092852900017089","volume":"13","author":"SM Stahl","year":"2008","unstructured":"Stahl SM. Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008;13(12):1027\u201338.","journal-title":"CNS Spectr"},{"key":"10_CR31","unstructured":"Aziende Chimiche Riunite Angelini Francesco (ACRAF SpA). Trittico (trazodone hydrochloride) 75\u00a0mg and 150\u00a0mg prolonged-release tablets: summary of the product characteristics. http:\/\/www.angelini.it\/public\/schedepharma\/trittico_rilascio_prolung.htm . Accessed June 15 2012."},{"key":"10_CR32","unstructured":"Medicines and Healthcare Products Regulatory Agency. Trazodone hydrochloride 50\u00a0mg and 100\u00a0mg capsules: summary of the product characteristics. http:\/\/www.mhra.gov.uk\/home\/groups\/l-unit1\/documents\/websiteresources\/con2023774.pdf . Accessed 22 Aug 2012."},{"key":"10_CR33","unstructured":"Oleptro\u2122 (trazodone hydrochloride) extended-release tablets. P T 2011;36(2):2\u201318."},{"issue":"1","key":"10_CR34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/106002808201600102","volume":"16","author":"WN Rawls","year":"1982","unstructured":"Rawls WN. Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). Drug Intell Clin Pharm. 1982;16(1):7\u201313.","journal-title":"Drug Intell Clin Pharm"},{"issue":"12","key":"10_CR35","doi-asserted-by":"crossref","first-page":"730","DOI":"10.5414\/CP201546","volume":"49","author":"D Karhu","year":"2011","unstructured":"Karhu D, Gossen ER, Mostert A, et al. Safety, tolerability, and pharmacokinetics of once-daily trazodone extended-release caplets in healthy subjects. Int J Clin Pharm Ther. 2011;49(12):730\u201343.","journal-title":"Int J Clin Pharm Ther"},{"issue":"7","key":"10_CR36","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.eurpsy.2007.01.1220","volume":"22","author":"GI Papakostas","year":"2007","unstructured":"Papakostas GI, Fava M. A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Psychiatry. 2007;22(7):444\u20137.","journal-title":"Eur Psychiatry"},{"issue":"7","key":"10_CR37","first-page":"294","volume":"52","author":"CM Beasley Jr","year":"1991","unstructured":"Beasley CM Jr, Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry. 1991;52(7):294\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10_CR38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00004714-199404000-00003","volume":"14","author":"LA Cunningham","year":"1994","unstructured":"Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol. 1994;14(2):99\u2013106.","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"10_CR39","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1185\/030079905X53243","volume":"21","author":"S Kasper","year":"2005","unstructured":"Kasper S, Olivieri L, Di Loreto G, Dionisio P. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin. 2005;21(8):1139\u201346.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10_CR40","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1185\/03007999009111497","volume":"12","author":"CA Moon","year":"1990","unstructured":"Moon CA, Laws D, Stott PC, Hayes G. Efficacy and tolerability of controlled-release trazodone in depression: a large multicentre study in general practice. Curr Med Res Opin. 1990;12(3):160\u20138.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"10_CR41","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1185\/030079906X121039","volume":"22","author":"C Munizza","year":"2006","unstructured":"Munizza C, Olivieri L, Di Loreto G, Dionisio P. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin. 2006;22(9):1703\u201313.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10_CR42","first-page":"20","volume":"6","author":"DV Sheehan","year":"2009","unstructured":"Sheehan DV, Croft HA, Gossen ER, et al. Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry. 2009;6(5):20\u201333.","journal-title":"Psychiatry"},{"issue":"4","key":"10_CR43","first-page":"5","volume":"42","author":"DV Sheehan","year":"2009","unstructured":"Sheehan DV, Rozova A, Gossen ER, Gibertini M. The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. Psychopharmacol Bull. 2009;42(4):5\u201322.","journal-title":"Psychopharmacol Bull"},{"issue":"1","key":"10_CR44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00004850-199503000-00001","volume":"10","author":"M Moffaert van","year":"1995","unstructured":"van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol. 1995;10(1):3\u20139.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"10_CR45","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00004714-199406000-00004","volume":"14","author":"RH Weisler","year":"1994","unstructured":"Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol. 1994;14(3):170\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl","key":"10_CR46","first-page":"S18","volume":"95","author":"R Blacker","year":"1988","unstructured":"Blacker R, Shanks NJ, Chapman N, Davey A. The drug treatment of depression in general practice: a comparison of nocte administration of trazodone with mianserin, dothiepin and amitriptyline. Psychopharmacology. 1988;95(Suppl):S18\u201324.","journal-title":"Psychopharmacology"},{"key":"10_CR47","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1192\/bjp.155.4.479","volume":"155","author":"WA Botros","year":"1989","unstructured":"Botros WA, Ankier SI, Priest RG, et al. Clinical assessment and performance tasks in depression: a comparison of amitriptyline and trazodone. Br J Psychiatry. 1989;155:479\u201382.","journal-title":"Br J Psychiatry"},{"issue":"Suppl","key":"10_CR48","first-page":"S25","volume":"95","author":"A Davey","year":"1988","unstructured":"Davey A. A comparison of two oral dosage regimens of 150\u00a0mg trazodone in the treatment of depression in general practice. Psychopharmacology. 1988;95(Suppl):S25\u201330.","journal-title":"Psychopharmacology"},{"issue":"11","key":"10_CR49","first-page":"422","volume":"49","author":"JR Debus","year":"1988","unstructured":"Debus JR, Rush AJ, Himmel C, et al. Fluoxetine versus trazodone in the treatment of outpatients with major depression. J Clin Psychiatry. 1988;49(11):422\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl","key":"10_CR50","first-page":"S7","volume":"95","author":"CA Moon","year":"1988","unstructured":"Moon CA, Davey A. The efficacy and residual effects of trazodone (150\u00a0mg nocte) and mianserin in the treatment of depressed general practice patients. Psychopharmacology. 1988;95(Suppl):S7\u201313.","journal-title":"Psychopharmacology"},{"key":"10_CR51","doi-asserted-by":"crossref","unstructured":"Altamura AC, Mauri MC, Rudas N, et al. Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression: a controlled multicenter trial. Clin Neuropharmacol. 1989;12(Suppl 1):S25\u201333 (S4\u20137).","DOI":"10.1097\/00002826-198901001-00005"},{"issue":"5","key":"10_CR52","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1742-1241.1985.tb07814.x","volume":"39","author":"SA Ather","year":"1985","unstructured":"Ather SA, Ankier SI, Middleton RS. A double-blind evaluation of trazodone in the treatment of depression in the elderly. Br J Clin Pract. 1985;39(5):192\u20139.","journal-title":"Br J Clin Pract"},{"issue":"6","key":"10_CR53","first-page":"216","volume":"41","author":"R Gerner","year":"1980","unstructured":"Gerner R, Estabrook W, Steuer J, Jarvik L. Treatment of geriatric depression with trazodone, imipramine, and placebo: a double-blind study. J Clin Psychiatry. 1980;41(6):216\u201320.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10_CR54","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/089198878900200407","volume":"2","author":"WE Falk","year":"1989","unstructured":"Falk WE, Rosenbaum JF, Otto MW, et al. Fluoxetine versus trazodone in depressed geriatric patients. J Geriatr Psychiatry Neurol. 1989;2(4):208\u201314.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10_CR55","doi-asserted-by":"crossref","unstructured":"Bayer AJ, Pathy MS, Cameron A, et al. A comparative study of conventional and controlled-release formulations of trazodone in elderly depressed patients. Clin Neuropharmacol. 1989;12(Suppl 1):S50\u20135 (discussion S6\u20137).","DOI":"10.1097\/00002826-198901001-00009"},{"issue":"11","key":"10_CR56","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/00004583-199811000-00029","volume":"37","author":"B Birmaher","year":"1998","unstructured":"Birmaher B, Brent DA, Benson RS. Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders: American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1998;37(11):1234\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"10_CR57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1089\/cap.2000.10.307","volume":"10","author":"L Saccomani","year":"2000","unstructured":"Saccomani L, Rizzo P, Nobili L. Combined treatment with haloperidol and trazodone in patients with tic disorders. J Child Adolesc Psychopharmacol. 2000;10(4):307\u201310.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"10_CR58","first-page":"424","volume":"117","author":"B Catanese","year":"1978","unstructured":"Catanese B, Dionisio A, Barillari G, De Martino C. A comparative study of trazodone serum concentrations in patients with normal or impaired renal function. Boll Chim Farm. 1978;117(7):424\u20137.","journal-title":"Boll Chim Farm"},{"issue":"8","key":"10_CR59","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1016\/j.transproceed.2009.09.022","volume":"41","author":"O Detry","year":"2009","unstructured":"Detry O, Delwaide J, De Roover A, et al. Fulminant hepatic failure induced by venlafaxine and trazodone therapy: a case report. Transplant Proc. 2009;41(8):3435\u20136.","journal-title":"Transplant Proc"},{"issue":"Suppl 2","key":"10_CR60","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000284097","volume":"17","author":"A Agnoli","year":"1984","unstructured":"Agnoli A, De Gregorio M, Dionisio A. Trazodone, a review of clinical literature and personal experience. Psychopathology. 1984;17(Suppl 2):88\u2013103.","journal-title":"Psychopathology"},{"issue":"4","key":"10_CR61","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00002512-199404040-00006","volume":"4","author":"M Haria","year":"1994","unstructured":"Haria M, Fitton A, McTavish D. Trazodone: a review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 1994;4(4):331\u201355.","journal-title":"Drugs Aging"},{"issue":"5","key":"10_CR62","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF00605991","volume":"23","author":"CD Burgess","year":"1982","unstructured":"Burgess CD, Hames TK, George CF. The electrocardiographic and anticholinergic effects of trazodone and imipramine in man. Eur J Clin Pharmacol. 1982;23(5):417\u201321.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10_CR63","first-page":"272","volume":"20","author":"AH Glassman","year":"1984","unstructured":"Glassman AH. The newer antidepressant drugs and their cardiovascular effects. Psychopharmacol Bull. 1984;20(2):272\u20139.","journal-title":"Psychopharmacol Bull"},{"issue":"4","key":"10_CR64","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1179\/acb.2001.038","volume":"56","author":"A Meester de","year":"2001","unstructured":"de Meester A, Carbutti G, Gabriel L, Jacques JM. Fatal overdose with trazodone: case report and literature review. Acta Clin Belg. 2001;56(4):258\u201361.","journal-title":"Acta Clin Belg"},{"issue":"7","key":"10_CR65","first-page":"388","volume":"47","author":"MD Aronson","year":"1986","unstructured":"Aronson MD, Hafez H. A case of trazodone-induced ventricular tachycardia. J Clin Psychiatry. 1986;47(7):388\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10_CR66","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1378\/chest.98.1.247","volume":"98","author":"RN Vitullo","year":"1990","unstructured":"Vitullo RN, Wharton JM, Allen NB, Pritchett EL. Trazodone-related exercise-induced nonsustained ventricular tachycardia. Chest. 1990;98(1):247\u20138.","journal-title":"Chest"},{"issue":"1","key":"10_CR67","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/hup.746","volume":"21","author":"D Winkler","year":"2006","unstructured":"Winkler D, Ortner R, Pjrek E, et al. Trazodone-induced cardiac arrhythmias: a report of two cases. Hum Psychopharmacol. 2006;21(1):61\u20132.","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"10_CR68","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4088\/JCP.v66n0409","volume":"66","author":"WB Mendelson","year":"2005","unstructured":"Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66(4):469\u201376.","journal-title":"J Clin Psychiatry"},{"issue":"1\u20132","key":"10_CR69","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2005.01.009","volume":"510","author":"P Tarantino","year":"2005","unstructured":"Tarantino P, Appleton N, Lansdell K. Effect of trazodone on hERG channel current and QT-interval. Eur J Pharmacol. 2005;510(1\u20132):75\u201385.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10_CR70","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1176\/appi.psy.46.4.367","volume":"46","author":"G Jayaram","year":"2005","unstructured":"Jayaram G, Rao P. Safety of trazodone as a sleep agent for inpatients. Psychosomatics. 2005;46(4):367\u20139.","journal-title":"Psychosomatics"},{"issue":"3","key":"10_CR71","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00002826-200305000-00006","volume":"26","author":"R Stryjer","year":"2003","unstructured":"Stryjer R, Strous RD, Bar F, et al. Treatment of neuroleptic-induced akathisia with the 5-HT2A antagonist trazodone. Clin Neuropharmacol. 2003;26(3):137\u201341.","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"10_CR72","first-page":"430","volume":"51","author":"JW Thompson Jr","year":"1990","unstructured":"Thompson JW Jr, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. J Clin Psychiatry. 1990;51(10):430\u20133.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10_CR73","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5414\/CPP42120","volume":"42","author":"M Prapotnik","year":"2004","unstructured":"Prapotnik M, Waschgler R, Konig P, et al. Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine? Int J Clin Pharm Ther. 2004;42(2):120\u20134.","journal-title":"Int J Clin Pharm Ther"},{"issue":"1","key":"10_CR74","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.phrs.2004.06.007","volume":"51","author":"G Bertschy","year":"2005","unstructured":"Bertschy G, Ragama-Pardos E, Muscionico M, et al. Trazodone addition for insomnia in venlafaxine-treated, depressed inpatients: a semi-naturalistic study. Pharmacol Res. 2005;51(1):79\u201384.","journal-title":"Pharmacol Res"},{"issue":"1","key":"10_CR75","first-page":"17","volume":"44","author":"LF Fabre Jr","year":"1983","unstructured":"Fabre LF Jr, Feighner JP. Long-term therapy for depression with trazodone. J Clin Psychiatry. 1983;44(1):17\u201321.","journal-title":"J Clin Psychiatry"},{"key":"10_CR76","doi-asserted-by":"crossref","unstructured":"Bossini L, Casolaro I, Koukouna D, et al. Off-label uses of trazodone: a review. Expert Opin Pharmacother. 2012;13(12):1707\u201317.","DOI":"10.1517\/14656566.2012.699523"},{"key":"10_CR77","unstructured":"Ancoli-Israel S. Insomnia in the elderly: a review for the primary care practitioner. Sleep 2000;23(Suppl 1):S23\u201330 (discussion S6\u20138)."},{"issue":"2","key":"10_CR78","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0278-5846(01)00262-7","volume":"26","author":"GM Saletu-Zyhlarz","year":"2002","unstructured":"Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(2):249\u201360.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"10_CR79","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000054934","volume":"44","author":"GM Saletu-Zyhlarz","year":"2001","unstructured":"Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia related to dysthymia: polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone. Neuropsychobiol. 2001;44(3):139\u201349.","journal-title":"Neuropsychobiol"},{"issue":"1","key":"10_CR80","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10401230500464711","volume":"18","author":"RP Rosenberg","year":"2006","unstructured":"Rosenberg RP. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry. 2006;18(1):49\u201356.","journal-title":"Ann Clin Psychiatry"},{"issue":"2","key":"10_CR81","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2125.1983.tb04977.x","volume":"16","author":"I Montgomery","year":"1983","unstructured":"Montgomery I, Oswald I, Morgan K, Adam K. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol. 1983;16(2):139\u201344.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10_CR82","first-page":"607","volume":"3","author":"D Wheatley","year":"1984","unstructured":"Wheatley D. Trazodone: alternative dose regimens and sleep. Pharmatherapeutica. 1984;3(9):607\u201312.","journal-title":"Pharmatherapeutica"},{"key":"10_CR83","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/(SICI)1099-1077(199804)13:3<191::AID-HUP972>3.0.CO;2-X","volume":"13","author":"JB Walsh","year":"1998","unstructured":"Walsh JB, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol. 1998;13:191\u20138.","journal-title":"Hum Psychopharmacol"},{"issue":"7","key":"10_CR84","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1176\/ajp.151.7.1069","volume":"151","author":"AA Nierenberg","year":"1994","unstructured":"Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry. 1994;151(7):1069\u201372.","journal-title":"Am J Psychiatry"},{"issue":"Suppl","key":"10_CR85","first-page":"13","volume":"51","author":"MB Scharf","year":"1990","unstructured":"Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry. 1990;51(Suppl):13\u20137.","journal-title":"J Clin Psychiatry"},{"key":"10_CR86","unstructured":"Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry. 1999;60(Suppl)17:28\u201331 (discussion 46\u20138)."},{"issue":"2","key":"10_CR87","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/cap.1997.7.97","volume":"7","author":"BR Kallepalli","year":"1997","unstructured":"Kallepalli BR, Bhatara VS, Fogas BS, et al. Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders. J Child Adolesc Psychopharmacol. 1997;7(2):97\u2013107.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"10_CR88","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0924-9338(99)80736-6","volume":"14","author":"PM Haffmans","year":"1999","unstructured":"Haffmans PM, Vos MS. The effects of trazodone on sleep disturbances induced by brofaromine. Eur Psychiatry. 1999;14(3):167\u201371.","journal-title":"Eur Psychiatry"},{"issue":"3","key":"10_CR89","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s002130050997","volume":"144","author":"CR Rush","year":"1999","unstructured":"Rush CR, Baker RW, Wright K. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology. 1999;144(3):220\u201333.","journal-title":"Psychopharmacology"},{"issue":"1","key":"10_CR90","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s002130050259","volume":"131","author":"CR Rush","year":"1997","unstructured":"Rush CR, Madakasira S, Hayes CA, et al. Trazodone and triazolam: acute subject-rated and performance-impairing effects in healthy volunteers. Psychopharmacology. 1997;131(1):9\u201318.","journal-title":"Psychopharmacology"},{"issue":"2","key":"10_CR91","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF01321316","volume":"15","author":"CP Pollak","year":"1990","unstructured":"Pollak CP, Perlick D, Linsner JP, et al. Sleep problems in the community elderly as predictors of death and nursing home placement. J Community Health. 1990;15(2):123\u201335.","journal-title":"J Community Health"},{"key":"10_CR92","unstructured":"Wittchen HU, Lieb R, Wunderlich U, Schuster P. Comorbidity in primary care: presentation and consequences. J Clin Psychiatry. 1999;60(Suppl 7):29\u201336 (discussion 7\u20138)."},{"issue":"4","key":"10_CR93","first-page":"283","volume":"44","author":"CK Gale","year":"2002","unstructured":"Gale CK. The treatment of generalised anxiety disorder: a systematic review. Panminerva Med. 2002;44(4):283\u20136.","journal-title":"Panminerva Med"},{"issue":"11","key":"10_CR94","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archpsyc.1993.01820230054005","volume":"50","author":"K Rickels","year":"1993","unstructured":"Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50(11):884\u201395.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10_CR95","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/00004714-199608000-00004","volume":"16","author":"MA Hertzberg","year":"1996","unstructured":"Hertzberg MA, Feldman ME, Beckham JC, Davidson JR. Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J Clin Psychopharmacol. 1996;16(4):294\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10_CR96","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-2001-15871","volume":"34","author":"MD Warner","year":"2001","unstructured":"Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry. 2001;34(4):128\u201331.","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10_CR97","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1176\/ajp.144.6.785","volume":"144","author":"M Mavissakalian","year":"1987","unstructured":"Mavissakalian M, Perel J, Bowler K, Dealy R. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry. 1987;144(6):785\u20137.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"10_CR98","first-page":"580","volume":"47","author":"DS Charney","year":"1986","unstructured":"Charney DS, Woods SW, Goodman WK, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry. 1986;47(12):580\u20136.","journal-title":"J Clin Psychiatry"},{"key":"10_CR99","unstructured":"Milton S, Hershey Medical Center. Efficacy of trazodone vs. cognitive behavioral therapy in patients with chronic insomnia associated with objective short sleep duration [ClinicalTrials.gov identifier NCT01348542]. US National Institutes of Health, ClinicalTrials.gov. http:\/\/www.clinicaltrials.gov . Accessed 5 June 2012."},{"issue":"6","key":"10_CR100","first-page":"895","volume":"29","author":"L Zavesicka","year":"2008","unstructured":"Zavesicka L, Brunovsky M, Horacek J, et al. Trazodone improves the results of cognitive behaviour therapy of primary insomnia in non-depressed patients. Neuro Endocrinol Lett. 2008;29(6):895\u2013901.","journal-title":"Neuro Endocrinol Lett"},{"issue":"1","key":"10_CR101","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.sleep.2003.06.006","volume":"5","author":"H Kaynak","year":"2004","unstructured":"Kaynak H, Kaynak D, Gozukirmizi E, Guilleminault C. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med. 2004;5(1):15\u201320.","journal-title":"Sleep Med"},{"issue":"2","key":"10_CR102","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1440-1819.1999.00531.x","volume":"53","author":"H Yamadera","year":"1999","unstructured":"Yamadera H, Suzuki H, Nakamura S, Endo S. Effects of trazodone on polysomnography, blood concentration and core body temperature in healthy volunteers. Psychiatry Clin Neurosci. 1999;53(2):189\u201391.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"Suppl","key":"10_CR103","first-page":"S37","volume":"95","author":"J Mouret","year":"1988","unstructured":"Mouret J, Lemoine P, Minuit MP, et al. Effects of trazodone on the sleep of depressed subjects: a polygraphic study. Psychopharmacology. 1988;95(Suppl):S37\u201343.","journal-title":"Psychopharmacology"},{"issue":"4","key":"10_CR104","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF02247467","volume":"116","author":"L Parrino","year":"1994","unstructured":"Parrino L, Spaggiari MC, Boselli M, et al. Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. Psychopharmacology. 1994;116(4):389\u201395.","journal-title":"Psychopharmacology"},{"issue":"4","key":"10_CR105","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/BF02245272","volume":"107","author":"AL Bemmel van","year":"1992","unstructured":"van Bemmel AL, Havermans RG, van Diest R. Effects of trazodone on EEG sleep and clinical state in major depression. Psychopharmacology. 1992;107(4):569\u201374.","journal-title":"Psychopharmacology"},{"issue":"Suppl","key":"10_CR106","first-page":"18","volume":"51","author":"JC Ware","year":"1990","unstructured":"Ware JC, Pittard JT. Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. J Clin Psychiatry. 1990;51(Suppl):18\u201322.","journal-title":"J Clin Psychiatry"},{"key":"10_CR107","unstructured":"Data on file, Angelini (2012)."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-012-0010-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T17:25:00Z","timestamp":1687886700000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-012-0010-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,13]]},"references-count":107,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1007\/s40263-012-0010-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,13]]}}}